$MLSS
MILESTONE SCIENTIFIC INC. Stock $mlss

$mlss Overview Financials Valuation SEC Filings Company Website

2013 Q2 Form 10-Q Financial Statement

#000156459013000230 Filed on August 08, 2013

Income Statement

Concept	2013 Q2	2012 Q2
Revenue	$2.280M	$2.330M
YoY Change	-2.15%	-5.28%
Cost Of Revenue	$740.0K	$850.0K
YoY Change	-12.94%	-2.3%
Gross Profit	$1.530M	$1.470M
YoY Change	4.08%	-8.13%
Gross Profit Margin	67.11%	63.09%
Selling, General & Admin	$1.340M	$1.490M
YoY Change	-10.07%	-17.22%
% of Gross Profit	87.58%	101.36%
Research & Development	$40.00K	$40.00K
YoY Change	0.0%	-33.33%
% of Gross Profit	2.61%	2.72%
Depreciation & Amortization	$30.00K	$20.00K
YoY Change	50.0%	0.0%
% of Gross Profit	1.96%	1.36%
Operating Expenses	$1.390M	$1.530M
YoY Change	-9.15%	-17.74%
Operating Profit	$140.0K	-$60.00K
YoY Change	-333.33%	-76.92%
Interest Expense	$30.01K	-$110.0K
YoY Change	-127.28%	175.0%
% of Operating Profit	21.44%
Other Income/Expense, Net	$77.10K	$110.9K
YoY Change	-30.5%
Pretax Income	$70.00K	-$160.0K
YoY Change	-143.75%	-46.67%
Income Tax	$0.00	$0.00
% Of Pretax Income	0.0%
Net Earnings	$74.01K	-$164.5K
YoY Change	-144.98%	-45.15%
Net Earnings / Revenue	3.25%	-7.06%
Basic Earnings Per Share	$0.00	-$0.01
Diluted Earnings Per Share	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	16.74M	15.98M
Diluted Shares Outstanding	17.06M	15.98M

Balance Sheet

Concept	2013 Q2	2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$170.0K	$120.0K
YoY Change	41.67%	20.0%
Cash & Equivalents	$171.6K	$121.8K
Short-Term Investments
Other Short-Term Assets	$160.0K	$300.0K
YoY Change	-46.67%	7.14%
Inventory	$857.1K	$1.450M
Prepaid Expenses
Receivables	$1.061M	$1.080M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.760M	$2.960M
YoY Change	-6.77%	-12.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$30.64K	$40.00K
YoY Change	-23.4%	-33.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$50.00K	$0.00
YoY Change
Other Assets	$7.317K	$90.00K
YoY Change	-91.87%	-10.0%
Total Long-Term Assets	$2.878M	$3.300M
YoY Change	-12.78%	-17.29%
TOTAL ASSETS
Total Short-Term Assets	$2.760M	$2.960M
Total Long-Term Assets	$2.878M	$3.300M
Total Assets	$5.638M	$6.260M
YoY Change	-9.94%	-15.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.506M	$3.090M
YoY Change	-51.27%	6.92%
Accrued Expenses	$410.0K	$830.0K
YoY Change	-50.6%	-22.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.526M	$3.920M
YoY Change	-35.57%	-1.01%
LONG-TERM LIABILITIES
Long-Term Debt	$450.0K	$450.0K
YoY Change	0.0%	-65.65%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$450.0K	$450.0K
YoY Change	0.0%	-65.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.526M	$3.920M
Total Long-Term Liabilities	$450.0K	$450.0K
Total Liabilities	$2.976M	$4.370M
YoY Change	-31.91%	-17.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$61.51M
YoY Change
Common Stock	$65.08M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$911.5K
YoY Change
Treasury Stock Shares	$33.33K
Shareholders Equity	$2.662M	$1.890M
YoY Change
Total Liabilities & Shareholders Equity	$5.638M	$6.260M
YoY Change	-9.94%	-15.18%

Cashflow Statement

Concept	2013 Q2	2012 Q2
OPERATING ACTIVITIES
Net Income	$74.01K	-$164.5K
YoY Change	-144.98%	-45.15%
Depreciation, Depletion And Amortization	$30.00K	$20.00K
YoY Change	50.0%	0.0%
Cash From Operating Activities	$90.00K	$10.00K
YoY Change	800.0%	-125.0%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$10.00K
YoY Change	0.0%	-50.0%
Acquisitions
YoY Change
Other Investing Activities	-$50.00K
YoY Change
Cash From Investing Activities	-$60.00K	-$10.00K
YoY Change	500.0%	-50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	0.000
YoY Change
NET CHANGE
Cash From Operating Activities	90.00K	10.00K
Cash From Investing Activities	-60.00K	-10.00K
Cash From Financing Activities	10.00K	0.000
Net Change In Cash	40.00K	-0.000000000005457
YoY Change	-733007751850666800.0%	-100.0%
FREE CASH FLOW
Cash From Operating Activities	$90.00K	$10.00K
Capital Expenditures	-$10.00K	-$10.00K
Free Cash Flow	$100.0K	$20.00K
YoY Change	400.0%	-200.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2336594
CY2013Q2	us-gaap	Interest Payable Current InterestPayableCurrent	405202
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2012Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	450000
CY2013Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	0
CY2012Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	119201
CY2012Q4	mlss	Advances To Contract Manufacturer Non Current AdvancesToContractManufacturerNonCurrent	2350477
CY2013Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	450000
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	581407
CY2013Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	450000
CY2012Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	450000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5637785
CY2013Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	73849
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Noncurrent AllowanceForDoubtfulAccountsReceivableNoncurrent	167971
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16563306
CY2012Q4	mlss	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	1635709
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16529973
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	33333
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4767778
CY2013Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	467483
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5661103
CY2012Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	179259
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	420556
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	165249
CY2012Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	458708
CY2013Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	459380
CY2013Q2	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	508469
CY2013Q2	mlss	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	161155
CY2013Q2	us-gaap	Equity Method Investments EquityMethodInvestments	50000
CY2013Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36624
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7317
CY2012Q4	us-gaap	Assets Assets	5661103
CY2013Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2525672
CY2013Q2	us-gaap	Inventory Net InventoryNet	857120
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	648662
CY2013Q2	us-gaap	Assets Current AssetsCurrent	2759519
CY2013Q2	mlss	Advances To Contract Manufacturer Non Current AdvancesToContractManufacturerNonCurrent	2163907
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	978982
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61730368
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	911516
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	18199
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	64560224
CY2013Q2	us-gaap	Liabilities Liabilities	2975672
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	1936539
CY2012Q4	us-gaap	Liabilities Liabilities	3724564
	dei	Entity Registrant Name EntityRegistrantName	MILESTONE SCIENTIFIC INC.
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Document Period End Date DocumentPeriodEndDate	2013-06-30
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3274564
	dei	Entity Central Index Key EntityCentralIndexKey	0000855683
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	171640
CY2013Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16957711
	dei	Document Type DocumentType	10-Q
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2728031
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2939326
	us-gaap	Gross Profit GrossProfit	3211626
CY2013Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1061135
CY2013Q2	mlss	Accrued Expenses And Other Payable Current AccruedExpensesAndOtherPayableCurrent	614681
CY2012Q4	mlss	Accrued Expenses And Other Payable Current AccruedExpensesAndOtherPayableCurrent	356563
CY2013Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2013Q2	mlss	Common Stock Shares To Be Issued CommonStockSharesToBeIssued	1655317
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1556152
CY2013Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30640
CY2013Q2	us-gaap	Assets Assets	5637785
CY2013Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	626402
CY2013Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7317
CY2013Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1505789
CY2013Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17056219
CY2012Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15975822
CY2012Q4	us-gaap	Inventory Net InventoryNet	638561
CY2012Q4	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	476969
CY2012Q4	mlss	Prepaid Expenses And Other Current Assets PrepaidExpensesAndOtherCurrentAssets	239061
CY2012Q4	us-gaap	Assets Current AssetsCurrent	2498822
CY2013Q2	us-gaap	Common Stock Value CommonStockValue	18585
CY2013Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	65060658
CY2013Q2	us-gaap	Treasury Stock Value TreasuryStockValue	911516
CY2013Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-61505614
CY2013Q2	us-gaap	Stockholders Equity StockholdersEquity	2662113
	us-gaap	Gross Profit GrossProfit	2731383
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4248334
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1516951
	us-gaap	Operating Expenses OperatingExpenses	3018140
	us-gaap	Operating Income Loss OperatingIncomeLoss	-286757
CY2013Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-47093
CY2013Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16896245
CY2013Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	33333
CY2013Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16929578
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	164722
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78814
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	74009
CY2012Q2	mlss	Number Of Customers NumberOfCustomers	2
	mlss	Stock Issued During Period Value Directors Compensation StockIssuedDuringPeriodValueDirectorsCompensation	45000
	mlss	Stock Issued During Period Value Non Employee Services StockIssuedDuringPeriodValueNonEmployeeServices	295000
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	23750
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	29600
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	50000
	us-gaap	Depreciation Depreciation	8775
	us-gaap	Operating Expenses OperatingExpenses	2892753
	us-gaap	Operating Income Loss OperatingIncomeLoss	318873
CY2013Q2	us-gaap	Interest Expense InterestExpense	30011
CY2013Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0.00
CY2012Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-46084
CY2013Q2	us-gaap	Other Expenses OtherExpenses	77104
CY2012Q2	us-gaap	Other Expenses OtherExpenses	110934
CY2012Q2	us-gaap	Net Income Loss NetIncomeLoss	-164541
CY2013Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2012Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2013Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2012Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
CY2013Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16744951
CY2012Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15975822
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37470
	mlss	Stock Issued During Period Value Employee For Bonuses StockIssuedDuringPeriodValueEmployeeForBonuses	20000
	us-gaap	Depreciation Depreciation	10047
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	38825
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37957
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0
	mlss	Common Stock And Options Issued For Compensation Consulting And Vendor Services CommonStockAndOptionsIssuedForCompensationConsultingAndVendorServices	383720
	mlss	Common Stock And Options Issued For Compensation Consulting And Vendor Services CommonStockAndOptionsIssuedForCompensationConsultingAndVendorServices	204156
	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	48639
	us-gaap	Interest Expense Other Long Term Debt InterestExpenseOtherLongTermDebt	42276
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-239501
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-78096
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-276549
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-205555
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	218559
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-276157
	mlss	Increase To Advances To Contract Manufacturer IncreaseToAdvancesToContractManufacturer	-155070
	mlss	Increase To Advances To Contract Manufacturer IncreaseToAdvancesToContractManufacturer	-171975
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-115406
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-44257
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-18003
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-830805
	mlss	Stock Issued Directors Compensation StockIssuedDirectorsCompensation	45000
	mlss	Stock Issued Employees Compensation StockIssuedEmployeesCompensation	23750
	mlss	Stock Issued Employees Compensation StockIssuedEmployeesCompensation	19375
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-846004
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1727
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	197243
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8239
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108952
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	50000
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	47093
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2790
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2611
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	16565
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12959
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-116448
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15570
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	29600
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	50000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150000
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	50000
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	15000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	114600
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	6391
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25478
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97324
CY2012Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	121802
	mlss	Stock Issued During Period To Purchase Option Of Directors Value StockIssuedDuringPeriodToPurchaseOptionOfDirectorsValue	29600
	mlss	Stock Issued Directors Compensation StockIssuedDirectorsCompensation	45000
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1445040
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	40000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	36666
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1207075
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	794620
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.79
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.74
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0.094
	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	845628
CY2013Q2	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	698591
CY2012Q4	us-gaap	Accounts Payable Related Parties Current And Noncurrent AccountsPayableRelatedPartiesCurrentAndNoncurrent	808908
CY2013Q2	mlss	Number Of Customers NumberOfCustomers	3
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.87
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.84
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y26D
	mlss	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm
CY2013Q2	mlss	Working Capital WorkingCapital	233847
CY2012Q4	mlss	Working Capital WorkingCapital	-775742
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	1009589
CY2013Q2	us-gaap	Related Party Transaction Due From To Related Party RelatedPartyTransactionDueFromToRelatedParty	450000
	us-gaap	Related Party Transaction Date RelatedPartyTransactionDate	2015-01-05
CY2013Q2	mlss	Remaining Balance Due From Distributer RemainingBalanceDueFromDistributer	128004
	mlss	Sales Credit Period SalesCreditPeriod	P60D
CY2012Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	0
	mlss	Instrument Development Period From Inception Date InstrumentDevelopmentPeriodFromInceptionDate	P30M
CY2013Q2	mlss	Investment To Medical Joint Venture InvestmentToMedicalJointVenture	0
	mlss	Number Of Development Of Products For Medical Joint Venture NumberOfDevelopmentOfProductsForMedicalJointVenture	2
	mlss	Number Of Development Of Instruments NumberOfDevelopmentOfInstruments	2
CY2013Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	500000
CY2013Q2	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.50
CY2013Q2	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	50000
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1283741
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
	mlss	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P2Y8M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y2M5D
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	768692
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	614768
CY2013Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	421506
CY2013Q2	mlss	Advances On Inventory Purchases Current And Non Current AdvancesOnInventoryPurchasesCurrentAndNonCurrent	2672376
CY2012Q4	mlss	Advances On Inventory Purchases Current And Non Current AdvancesOnInventoryPurchasesCurrentAndNonCurrent	2827446
CY2013Q2	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	136000
CY2012Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	705000
	mlss	Utilization Period Of Advance UtilizationPeriodOfAdvance	P12M
CY2008	us-gaap	Line Of Credit Facility Increase Additional Borrowings LineOfCreditFacilityIncreaseAdditionalBorrowings	450000
	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2009-01-19
	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.12
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	0.32
CY2013Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	45000
	mlss	Year Of Warrants Expired YearOfWarrantsExpired	2012
	mlss	Line Of Credit Facility Accrued Interest LineOfCreditFacilityAccruedInterest	405202
CY2012	mlss	Line Of Credit Facility Accrued Interest LineOfCreditFacilityAccruedInterest	356563
CY2009Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1300000
	mlss	Number Of Customers NumberOfCustomers	3
	mlss	Number Of Customers NumberOfCustomers	2
CY2013Q2	us-gaap	Entity Wide Revenue Major Customer Percentage EntityWideRevenueMajorCustomerPercentage	0.47
CY2013Q2	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	75795
CY2012Q4	us-gaap	Line Of Credit Facility Amount Outstanding LineOfCreditFacilityAmountOutstanding	72672
CY2013Q2	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.06
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	35714
CY2013Q2	us-gaap	Share Price SharePrice	1.40
	mlss	Stock Issued During Period Shares Directors Compensation StockIssuedDuringPeriodSharesDirectorsCompensation	39129
	mlss	Stock Issued During Period Shares Non Employee Directors Compensation StockIssuedDuringPeriodSharesNonEmployeeDirectorsCompensation	13043
	mlss	Shares Issued To Directors For Purchase Of Options SharesIssuedToDirectorsForPurchaseOfOptions	40000
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	19831
	mlss	Stock Issued During Period Shares Non Employee Services StockIssuedDuringPeriodSharesNonEmployeeServices	231598
	mlss	Stock Issued During Period Per Share Directors Compensation StockIssuedDuringPeriodPerShareDirectorsCompensation	0.74
	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	50000
	mlss	Stock Issued During Period Shares Directors Full Year Compensation StockIssuedDuringPeriodSharesDirectorsFullYearCompensation	30000
CY2012Q2	us-gaap	Entity Wide Revenue Major Customer Percentage EntityWideRevenueMajorCustomerPercentage	0.33
	us-gaap	Entity Wide Revenue Major Customer Percentage EntityWideRevenueMajorCustomerPercentage	0.34
	us-gaap	Entity Wide Revenue Major Customer Percentage EntityWideRevenueMajorCustomerPercentage	0.34
	mlss	Number Of Customers Involved In Accounts Receivables NumberOfCustomersInvolvedInAccountsReceivables	3
CY2012	mlss	Number Of Customers Involved In Accounts Receivables NumberOfCustomersInvolvedInAccountsReceivables	3
CY2013Q2	mlss	Accounts Receivable Net Current And Noncurrent Percentage AccountsReceivableNetCurrentAndNoncurrentPercentage	0.35
CY2012Q4	mlss	Accounts Receivable Net Current And Noncurrent Percentage AccountsReceivableNetCurrentAndNoncurrentPercentage	0.38
CY2013Q2	mlss	Accounts Receivable Net Current And Noncurrent AccountsReceivableNetCurrentAndNoncurrent	364666
CY2012Q4	mlss	Accounts Receivable Net Current And Noncurrent AccountsReceivableNetCurrentAndNoncurrent	421890
CY2013Q2	mlss	Consulting Fees To Director ConsultingFeesToDirector	39000
CY2012Q2	mlss	Consulting Fees To Director ConsultingFeesToDirector	39000
	mlss	Consulting Fees To Director ConsultingFeesToDirector	78000
	mlss	Consulting Fees To Director ConsultingFeesToDirector	78000
	mlss	Additional Payment To Director As Percentage Of Sales Value Using Certain Specify Technology AdditionalPaymentToDirectorAsPercentageOfSalesValueUsingCertainSpecifyTechnology	0.025
	mlss	Additional Payment To Director As Percentage Of Sales Value Using Other Kind Of Technology AdditionalPaymentToDirectorAsPercentageOfSalesValueUsingOtherKindOfTechnology	0.05
CY2013Q2	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	3095763
	mlss	Long Term Purchase Commitment Amount Available LongTermPurchaseCommitmentAmountAvailable	100000
CY2010Q1	us-gaap	Long Term Purchase Commitment Minimum Quantity Required LongTermPurchaseCommitmentMinimumQuantityRequired	12000
CY2013Q2	mlss	Joint Venture Expenses Incurred JointVentureExpensesIncurred	0
CY2010Q1	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	5261640

Files In Submission

Name	View Source	Status
0001564590-13-000230-index-headers.html	Edgar Link	pending
0001564590-13-000230-index.html	Edgar Link	pending
0001564590-13-000230.txt	Edgar Link	pending
0001564590-13-000230-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
mlss-10q_20130630.htm	Edgar Link	pending
mlss-20130630.xml	Edgar Link	completed
mlss-20130630.xsd	Edgar Link	pending
mlss-20130630_cal.xml	Edgar Link	unprocessable
mlss-20130630_def.xml	Edgar Link	unprocessable
mlss-20130630_lab.xml	Edgar Link	unprocessable
mlss-20130630_pre.xml	Edgar Link	unprocessable
mlss-ex31_20130629101.htm	Edgar Link	pending
mlss-ex31_20130629102.htm	Edgar Link	pending
mlss-ex32_20130629103.htm	Edgar Link	pending
mlss-ex32_20130629104.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R1.xml	Edgar Link	unprocessable
R10.htm	Edgar Link	pending
R10.xml	Edgar Link	unprocessable
R11.htm	Edgar Link	pending
R11.xml	Edgar Link	unprocessable
R12.htm	Edgar Link	pending
R12.xml	Edgar Link	unprocessable
R13.htm	Edgar Link	pending
R13.xml	Edgar Link	unprocessable
R14.htm	Edgar Link	pending
R14.xml	Edgar Link	unprocessable
R15.htm	Edgar Link	pending
R15.xml	Edgar Link	unprocessable
R16.htm	Edgar Link	pending
R16.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R17.xml	Edgar Link	unprocessable
R18.htm	Edgar Link	pending
R18.xml	Edgar Link	unprocessable
R19.htm	Edgar Link	pending
R19.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R2.xml	Edgar Link	unprocessable
R20.htm	Edgar Link	pending
R20.xml	Edgar Link	unprocessable
R21.htm	Edgar Link	pending
R21.xml	Edgar Link	unprocessable
R22.htm	Edgar Link	pending
R22.xml	Edgar Link	unprocessable
R23.htm	Edgar Link	pending
R23.xml	Edgar Link	unprocessable
R24.htm	Edgar Link	pending
R24.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R25.xml	Edgar Link	unprocessable
R26.htm	Edgar Link	pending
R26.xml	Edgar Link	unprocessable
R27.htm	Edgar Link	pending
R27.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R28.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R29.xml	Edgar Link	unprocessable
R3.htm	Edgar Link	pending
R3.xml	Edgar Link	unprocessable
R30.htm	Edgar Link	pending
R30.xml	Edgar Link	unprocessable
R31.htm	Edgar Link	pending
R31.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R32.xml	Edgar Link	unprocessable
R33.htm	Edgar Link	pending
R33.xml	Edgar Link	unprocessable
R34.htm	Edgar Link	pending
R34.xml	Edgar Link	unprocessable
R35.htm	Edgar Link	pending
R35.xml	Edgar Link	unprocessable
R36.htm	Edgar Link	pending
R36.xml	Edgar Link	unprocessable
R4.htm	Edgar Link	pending
R4.xml	Edgar Link	unprocessable
R5.htm	Edgar Link	pending
R5.xml	Edgar Link	unprocessable
R6.htm	Edgar Link	pending
R6.xml	Edgar Link	unprocessable
R7.htm	Edgar Link	pending
R7.xml	Edgar Link	unprocessable
R8.htm	Edgar Link	pending
R8.xml	Edgar Link	unprocessable
R9.htm	Edgar Link	pending
R9.xml	Edgar Link	unprocessable
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MLSS
MILESTONE SCIENTIFIC INC. Stock $mlss

2013 Q2 Form 10-Q Financial Statement

#000156459013000230 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLSS MILESTONE SCIENTIFIC INC. Stock $mlss

2013 Q2 Form 10-Q Financial Statement

#000156459013000230 Filed on August 08, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MLSS
MILESTONE SCIENTIFIC INC. Stock $mlss